for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bayer AG

BAYGn.DE

Latest Trade

49.51EUR

Change

0.31(+0.62%)

Volume

2,979,289

Today's Range

48.75

 - 

49.66

52 Week Range

39.91

 - 

78.34

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
49.21
Open
49.16
Volume
2,979,289
3M AVG Volume
91.98
Today's High
49.66
Today's Low
48.75
52 Week High
78.34
52 Week Low
39.91
Shares Out (MIL)
982.42
Market Cap (MIL)
48,639.82
Forward P/E
7.85
Dividend (Yield %)
5.66

Next Event

Q4 2020 Bayer AG Earnings Release

Latest Developments

More

Bayer Initiates New G4A Digital Health Partnerships Program

Bayer Acquires Majority Stake In Care/Of

Bayer Says FIDELIO-DKD Phase III Study Showed Finerenone Significantly Lowered Combined Risk Of Cardiovascular Events

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bayer AG

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

Industry

Major Drugs

Contact Info

Kaiser-Wilhelm-Allee 1

51373

Germany

+49.214.301

https://www.bayer.de/

Executive Leadership

Norbert Winkeljohann

Chairman of the Supervisory Board

Werner Baumann

Chairman of the Management Board, Chief Executive Officer

Oliver Zuehlke

Independent Vice Chairman of the Supervisory Board, Employee Representative

Wolfgang U. Nickl

Chief Financial Officer, Member of the Management Board

Liam Condon

Member of the Management Board, Head of the Crop Science Division, Animal Health Business Unit

Key Stats

2.23 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

35.0K

2018

39.6K

2019

43.5K

2020(E)

41.8K
EPS (EUR)

2017

6.633

2018

5.940

2019

6.400

2020(E)

6.315
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.15
Price To Book (MRQ)
1.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
138.70
LT Debt To Equity (MRQ)
112.33
Return on Investment (TTM)
-16.99
Return on Equity (TTM)
-12.77

Latest News

Latest News

Bayer makes 'substantial progress' in Roundup cancer lawsuits, mediator says

A court-appointed mediator on Monday said Bayer AG has made "substantial progress" toward resolving tens of thousands of remaining claims that its Roundup weedkiller causes cancer.

Bayer makes 'substantial progress' in Roundup cancer lawsuits, mediator says

A court-appointed mediator on Monday said Bayer AG has made "substantial progress" toward resolving tens of thousands of remaining claims that its Roundup weedkiller causes cancer.

Bayer executives buy 2.9 million euros in battered stock after writedowns

Bayer's CEO and two fellow executive board members purchased a collective 2.9 million euros ($3.5 million) worth of the German drugmaker's shares after the stock was battered by billions in writedowns, litigation woes and a bleaker profit outlook.

Bayer takes $10 billion writedown, flags higher Roundup settlement bill

Bayer is facing a double hit from a higher legal bill for claims relating to weedkiller Roundup as well as 9.25 billion euros ($10.82 billion) in impairments on agriculture businesses, much of it related to its Monsanto deal.

U.S. approves use of Bayer weed killer for five years

The U.S. Environmental Protection Agency said on Tuesday it will allow farmers to spray crops with weed killers based on the chemical dicamba that are sold by Bayer AG <BAYGn.DE> and other companies, after a U.S. appeals court blocked sales in June.

U.S. EPA approves use of controversial Bayer weed killer for five years -RFD TV

The U.S. Environmental Protection Agency will allow farmers for the next five years to spray crops with a Bayer AG weed killer that a U.S. appeals court blocked sales of in June, Administrator Andrew Wheeler said on RFD TV on Tuesday.

Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion

Bayer <BAYGn.DE> agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses.

Bayer drug shown to slow diabetic kidney disease

Bayer's finerenone drug slowed the progression of diabetic kidney disease in a late stage clinical trial, underscoring the company's hopes for the drug to generate at least 1 billion euros ($1.2 billion) in annual sales.

Monsanto loses final appeal over French farmer's weedkiller accident

Bayer's <BAYGn.DE> Monsanto division on Wednesday lost a final appeal in a long-running French legal battle in which the crop chemical maker has been held liable for the accidental inhalation of a weedkiller by a crop farmer.

France clamps down on use of weedkiller glyphosate in farming

France's health and environment agency announced restrictions on weedkiller glyphosate in farming, but stopped short of a full ban in the European Union's top agricultural producer due to a lack of non-chemical alternatives in some areas.

Bleaker profit outlook at Bayer turns into reckoning over Monsanto

Bayer shares <BAYGn.DE> plunged after it flagged lower profit next year and warned it may have to write down the value of agriculture assets by close to 10 billion euros ($11.7 billion), rekindling a debate over the merits of the takeover of Monsanto.

Bayer plans more cost cuts, impairment charges

German drugs company Bayer AG <BAYGn.DE> announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024 and said it would take impairment charges on its agricultural business as it battles with low commodity prices.

Bayer to cut more than 1.5 bln euros in costs

German drugs company Bayer AG announced plans on Wednesday for more than 1.5 billion euros ($1.76 billion)of cost cuts as of 2024, on top of savings announced in 2018, as it battles with a slowdown in the agricultural market.

Bayer resolves more Roundup cases, judge keeps pause on litigation

Attorneys for Bayer AG and consumers suing the company over allegations its Roundup weedkiller caused cancer told a judge on Thursday they are continuing to resolve thousands more cases, improving prospects for its $11 billion deal to end the litigation.

Exclusive: In the weeds - How Bayer, U.S. government teamed up against Thailand's glyphosate ban

Chemicals giant Bayer and the U.S. government cooperated closely last year to lobby Thailand to reverse its ban on glyphosate, used in the company's controversial weedkiller Roundup, documents obtained by an environmental group and reviewed by Reuters show.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer settles thousands of U.S. Roundup cases with trial attorneys

Bayer AG has settled thousands of U.S. Roundup weed killer lawsuits as part of an $11 billion settlement, reaching deals with the only lawyers who took cases to trial over allegations the herbicide caused cancer.

Bayer in deal with Systems Oncology over novel breast cancer drug

Bayer said on Tuesday it had secured the rights to an experimental breast cancer drug developed by U.S. biotech firm Systems Oncology LLC in a deal worth up to $370 million.

Bayer CEO's term extended, makes progress on Roundup settlement

Bayer boss Werner Baumann's contract has been extended until 2024, in a show of support from the drugmaker's new chairman just months after the company agreed an $11 billion outline settlement of U.S. lawsuits over its Roundup weedkiller.

Bayer appeals $20.5 million Roundup ruling to California Supreme Court

Bayer AG has asked California's Supreme Court to review a decision awarding $20.5 million to a groundskeeper who claimed the company's Roundup weedkiller caused his cancer, arguing the ruling was at odds with federal law and settled legal principles.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up